Nilotinib Capsule
Product Images NDC 31722-779

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Nilotinib (NDC 31722-779). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Nilotinib150mgwalletcarton (Nilotinib150mgwalletcarton)

This text provides information about Nilotinib Capsules, emphasizing the importance of taking them on an empty stomach. It includes details about the dosage, storage instructions, and contact information for the manufacturer. The medication guide must be dispensed to each patient, and the capsules come in a child-resistant package containing 4 individual blister packs, each with 28 capsules.*

FDA Label Image

Nilotinib150mgwalletpack (Nilotinib150mgwalletpack)

FDA Label Image

Nilotinib200mgwalletcarton (Nilotinib200mgwalletcarton)

This text provides detailed information about Nilotinib Capsules, including dosage instructions, storage guidelines, and manufacturer details. It highlights the importance of taking the capsules on an empty stomach and avoiding food before and after intake. The pack contains 4 blister packs, each with 28 capsules. The medication is for oral use and each capsule contains 200mg of nilotinib. The package is child-resistant and the medication guide should be dispensed separately to each patient. Remember to store the capsules at 20° to 25°C.*

FDA Label Image

Nilotinib200mgwalletpack (Nilotinib200mgwalletpack)

FDA Label Image

Nilotinibcamberlogo (Nilotinibcamberlogo)

FDA Label Image

Nilotinibchemicalstructure (Nilotinibchemicalstructure)

FDA Label Image

Nilotinibfigure1 (Nilotinibfigure1)

This text provides information about a study or analysis involving therapy cessation and censored observations. It includes data points related to the time when therapy was discontinued and the time since the therapy-free interval. The text also mentions specific time intervals and percentages, which may be important for conducting further analysis.*

FDA Label Image

Nilotinibfigure2 (Nilotinibfigure2)

This data shows the Treatment-free survival (%) over time since treatment. It includes information on the number of observations, censoring, and the time in weeks since treatment-free survival.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.